Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2000

View Archived Issues

Biomira reports update of drug development programs

Altea receives SBIR grant for noninvasive delivery of insulin research

Zycos licenses gene-based oncology product

Modafinil launched in Switzerland for treatment of narcolepsy

Valentis and Viragen combine PEGylation technology and Omniferon for HCV therapy

NO-releasing agents for chemoprevention of colon cancer focus of NCI grant

Asimadoline demonstrates diuretic effect in pharmacological study

Binding properties of potent antileukemic drug STI-571 revealed

Water-soluble inhibitors of Lp-PLA2: a novel approach to antiatherosclerotic therapy

ICAAC presentations cover in vitro and in vivo activity of new oral pleuromutilin

Contraceptive agents under investigation at French research institute

Selective V2 receptor agonists from AHP and their use described in patents

Trega invention relates to novel thiazole derivatives with antimicrobial activity

New series of MMP inhibitors for inhibiting tumor growth and metastasis

Inhibitors of ileal bile acid transport synthesized at Pharmacia

Prodrugs of NNRTIs presented in recent patent by Medivir

Exisulind/docetaxel combination prolongs survival in animal model of lung cancer

Positive results emerge from safety study with alpha1-antitrypsin in CF patients

Cognetix receives SBIR grant to develop conopeptides for chronic pain

Ariad and NsGene collaborate on CNS drug discovery

AMPA potentiators with oral bioavailability designed by Lilly

British Biotech turns focus to inhibitors of bacterial metalloenzymes as potential antimicrobials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...